Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sanofi-Genzyme BioVentures

Investor type Corporate Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 64
Average round size
info
The average size of a deal this fund participated in
$41M
Portfolio companies 51
Rounds per year 2.29
Lead investments 7
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 16
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Pharmaceutical
  • Medical
Summary

In 1994 was created Sanofi-Genzyme BioVentures, which is appeared as VC. The fund was located in North America if to be more exact in United States. Sanofi-Genzyme BioVentures appeared to be a CVC structure as part of the corporation. The leading representative office of defined VC is situated in the Cambridge.

The average startup value when the investment from Sanofi-Genzyme BioVentures is 100-500 millions dollars. The increased amount of exits for fund were in 2017. The real fund results show that this VC is 6 percentage points less often commits exit comparing to other companies. The top activity for fund was in 2017. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 deals per year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Opposing the other organizations, this Sanofi-Genzyme BioVentures works on 3 percentage points more the average amount of lead investments.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Sanofi-Genzyme BioVentures, startups are often financed by New Enterprise Associates, GE Ventures, U.S. Venture Partners (USVP). The meaningful sponsors for the fund in investment in the same round are New Enterprise Associates, Novartis Venture Fund, Atlas Venture. In the next rounds fund is usually obtained by Wellington Management, Rock Springs Capital, RA Capital Management.

For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Besides, a startup needs to be aged 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Therapeutics, Pharmaceutical. Among the most popular portfolio startups of the fund, we may highlight Omada Health, Expansion Therapeutics, Evidation Health.

The overall number of key employees were 4.

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
7 Industries Netherlands, Noord-Holland, North Holland
Aries Capital Partners Salt Lake City, United States, Utah
Camel Group China, Hubei, Xiangyang
Cypherpunk Holdings Inc. Canada, Ontario, Toronto
ETH Zurich Foundation Switzerland, Zürich, Zurich
Orchid India -
Shooting Star -
Silversmith Capital Partners Boston, Massachusetts, United States
Wasatch Funds Sandy, United States, Utah

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Normunity

Biotechnology
Medical
Therapeutics
$65M25 Oct 2022 West Haven, Connecticut, United States

Matchpoint Therapeutics

Biotechnology
Medical
Pharmaceutical
$70M14 Oct 2022 Cambridge, Massachusetts, United States

Empatica

Health Care
Wearables
$25M02 Aug 2022 Boston, Massachusetts, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$120M29 Jun 2022 Dallas, Texas, United States

OMass Technologies

Life Science
Pharmaceutical
$103M27 Apr 2022 Oxford, England, United Kingdom

Nucleai

Artificial Intelligence
Health Care
Machine Learning
$33M22 Mar 2022 Tel Aviv-Yafo, Tel Aviv District, Israel

Click Therapeutics

Biotechnology
Health Care
Information Technology
Medical Device
Other Healthcare Technology Systems
Pharmaceutical
Therapeutics
$52M22 Oct 2021 New York, New York, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$80M21 Oct 2021 Dallas, Texas, United States

Expansion Therapeutics

Biotechnology
Health Care
Therapeutics
$80M29 Sep 2021 San Diego, California, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sanofi-Genzyme BioVentures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: